At #ESMO26, Luigi Lorini discusses results of the phase 2 TEPMEETCET study of EGFR and c-MET inhibition in platinum- and IO-resistant recurrent/metastatic #HeadandNeckCancer, and w

返回会议原文

返回会议

VJ Oncology· @VJOncology · X·2026-10-24 22:44· 17 小时前评分45

EGFR

正文 · 机器翻译

在 #ESMO26，Luigi Lorini 介绍了 TEPMEETCET 2 期研究的结果。该研究针对铂类和 IO 耐药的复发/转移性 #HeadandNeckCancer，考察 EGFR 和 c-MET 抑制，以及这一策略能否提前应用

@myESMO #HNCSM #ImmunoOnc #TrialUpdate @HumanitasMilano

64 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2700RO按 Rapid oral 1: NSCLC, metastatic 对上

Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort

https://esmocongress.esmo.org

806PNCT04787341 NCT04787341 NCT04787341按 Colon cancer 对上

Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer

https://esmocongress.esmo.org

NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

来源：VJ Oncology · x.com